[
  {
    "ts": "2026-02-16T11:03:10+00:00",
    "headline": "Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026",
    "summary": "Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift towar",
    "url": "https://www.marketbeat.com/instant-alerts/zura-bio-highlights-key-phase-2-tibulizumab-readouts-at-guggenheim-biotech-summit-2026-2026-02-16/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "7c18d895-61f1-30ba-ab3c-7ec1d36d5736",
      "content": {
        "id": "7c18d895-61f1-30ba-ab3c-7ec1d36d5736",
        "contentType": "STORY",
        "title": "Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026",
        "description": "",
        "summary": "Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift towar",
        "pubDate": "2026-02-16T11:03:10Z",
        "displayTime": "2026-02-16T11:03:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/f07846d5c6302f81b43ab72c2cd1be36",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Zura Bio logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4oxwVeswpi92jVXcYfrNJA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/f07846d5c6302f81b43ab72c2cd1be36.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2LEamVq1HVpl0_z3uV_oxw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/f07846d5c6302f81b43ab72c2cd1be36.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/zura-bio-highlights-key-phase-2-tibulizumab-readouts-at-guggenheim-biotech-summit-2026-2026-02-16/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zura-bio-highlights-key-phase-110310812.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ZURA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]